BR112016017680A2 - asymmetric interference mRNA compositions that silence k-ras and methods of using them - Google Patents

asymmetric interference mRNA compositions that silence k-ras and methods of using them

Info

Publication number
BR112016017680A2
BR112016017680A2 BR112016017680A BR112016017680A BR112016017680A2 BR 112016017680 A2 BR112016017680 A2 BR 112016017680A2 BR 112016017680 A BR112016017680 A BR 112016017680A BR 112016017680 A BR112016017680 A BR 112016017680A BR 112016017680 A2 BR112016017680 A2 BR 112016017680A2
Authority
BR
Brazil
Prior art keywords
ras
silence
methods
asymmetric interference
mrna compositions
Prior art date
Application number
BR112016017680A
Other languages
Portuguese (pt)
Inventor
J Li Chiang
Original Assignee
Boston Biomedical Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boston Biomedical Inc filed Critical Boston Biomedical Inc
Priority claimed from PCT/US2015/020776 external-priority patent/WO2015139044A1/en
Publication of BR112016017680A2 publication Critical patent/BR112016017680A2/en

Links

Landscapes

  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

a invenção provê novas composições para uso em silenciamento de expressão de gene de k-ras. mais particularmente, a invenção provê novas moléculas de rna de interferência assimétrico como inibidores da expressão de k-ras, e as composições farmacêuticas e suas utilizações no tratamento de câncer ou de uma desordem relacionada em um mamífero.The invention provides novel compositions for use in k-ras gene expression silencing. more particularly, the invention provides novel asymmetric interference RNA molecules as inhibitors of k-ras expression, and pharmaceutical compositions and their uses in the treatment of cancer or a related disorder in a mammal.

BR112016017680A 2014-03-14 2015-03-16 asymmetric interference mRNA compositions that silence k-ras and methods of using them BR112016017680A2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461953590P 2014-03-14 2014-03-14
US201561121721P 2015-02-27 2015-02-27
PCT/US2015/020776 WO2015139044A1 (en) 2014-03-14 2015-03-16 Asymmetric interfering rna compositions that silence k-ras and methods of uses thereof

Publications (1)

Publication Number Publication Date
BR112016017680A2 true BR112016017680A2 (en) 2018-01-23

Family

ID=62598787

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112016017680A BR112016017680A2 (en) 2014-03-14 2015-03-16 asymmetric interference mRNA compositions that silence k-ras and methods of using them

Country Status (1)

Country Link
BR (1) BR112016017680A2 (en)

Similar Documents

Publication Publication Date Title
CY1122247T1 (en) CANCER INDUCTION USING PI3 KINASE ISOFORM MODIFIERS
CY1124407T1 (en) AUTOTAXIN INHIBITOR COMPOUNDS
BR112018072279A2 (en) oligonucleotide analogues targeting human lmna
EA201991369A1 (en) MODIFIED RNA GUIDES
CL2017000888A1 (en) Antibody molecules that bind to pd-l1 and uses thereof
BR112017024384A2 (en) bacteria modified to reduce hyperphenylalaninemia
PH12016500330B1 (en) Certain chemical entities, compositions, and methods
BR112014021498A2 (en) compound, composition and method for treating a disease associated with covalently closed circular DNA formation
BR112016029041A2 (en) combination therapy with glutaminase inhibitors
BR112016022785A2 (en) compound, pharmaceutical composition, pharmaceutical kit for treating a cancer, and methods of treating a disease and / or condition and / or disorder and synthesizing a compound
BR112017018954A2 (en) Use of Ras Protein Mutant Form and Method to Treat Cancer
EA201992251A1 (en) ANTI-CANCER VACCINES AND METHODS OF TREATMENT WITH THEIR APPLICATION
BR112014021104A2 (en) methods and compositions for the treatment of huntington's disease
MA40998A (en) THERAPIES AGAINST ENVENIMATION, AS WELL AS ASSOCIATED COMPOSITIONS, SYSTEMS AND PHARMACEUTICAL KITS
CL2016002495A1 (en) Macrocyclic pyridine derivatives.
MX2015014046A (en) Drug combinations to treat cancer.
CL2016002257A1 (en) Anti-mcam antibodies and associated methods of use
BR112018001853A2 (en) methods for treating a disorder and for improving the treatment of a disorder
BR112016017112A2 (en) APILIMOD COMPOSITIONS AND METHODS OF USE THEREOF
BR112017004056A2 (en) compositions and methods for detecting smn protein in an individual and treating an individual
BR112015023264A2 (en) method for extracorporeal oxygenation of an individual, and incubation apparatus
BR112018008882A8 (en) method for treating a proliferative disorder and pharmaceutical
CL2016003074A1 (en) Compounds derived from 2-oxy-2-phenyl-n-5-pyrrolidin-3-ylamino-1,3,4-thiadiazol-2-ylacetamide, pharmaceutical composition gls1 inhibitors and their use to treat cancer.
NI201600070A (en) AUTOTAXIN TETRAYCLIC INHIBITORS
MX2016002014A (en) Compositions and methods for modulating dna methylation.

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B08F Application fees: dismissal - article 86 of industrial property law

Free format text: REFERENTE A 5A ANUIDADE.

B08K Lapse as no evidence of payment of the annual fee has been furnished to inpi (acc. art. 87)

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2558 DE 14/01/2020.